The fragment corresponds to amino acid positions 176 to 191 of hGH and was identified as the region of the GH molecule responsible for its lipolytic fat-metabolising activity, separate from the anabolic and growth-promoting effects mediated by the GH receptor binding domains at the N-terminal end of the full molecule
Dihexa is now scheduled for PCAC review before the end of February 2027, alongside four other peptides: LL-37, GHK-Cu, PEG-MGF, and Melanotan II
Results are not immediate, but may be visible in a short period of time
it is degradation
Deeper Penetration: Reaches deeper tissue layers that topical formulations cannot access effectively
Heres what stands out: NAD+ therapy has been shown in multiple human studies to support mitochondrial health, cellular energy, cognitive function, and inflammation regulation